These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26902354)

  • 21. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.
    Zhang L; Han J
    Biochem Biophys Res Commun; 2017 Apr; 486(2):224-231. PubMed ID: 28235484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bovine lactoferrin induces cell cycle arrest and inhibits mTOR signaling in breast cancer cells.
    Zhang Y; Nicolau A; Lima CF; Rodrigues LR
    Nutr Cancer; 2014; 66(8):1371-85. PubMed ID: 25356800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
    Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
    Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin.
    Chen Q; Meng YQ; Xu XF; Gu J
    Anticancer Drugs; 2017 Sep; 28(8):880-887. PubMed ID: 28609310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-Glutamine enhances enterocyte growth via activation of the mTOR signaling pathway independently of AMPK.
    Yi D; Hou Y; Wang L; Ouyang W; Long M; Zhao D; Ding B; Liu Y; Wu G
    Amino Acids; 2015 Jan; 47(1):65-78. PubMed ID: 25280462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling.
    Scherbakov AM; Lobanova YS; Shatskaya VA; Krasil'nikov MA
    Steroids; 2009 Jun; 74(6):535-42. PubMed ID: 19428442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
    Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
    Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis.
    Wang B; Wang XB; Chen LY; Huang L; Dong RZ
    Biochem Biophys Res Commun; 2013 Jul; 437(1):1-6. PubMed ID: 23743198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells.
    Wang Q; Luo C; Wu X; Du H; Song X; Fan Y
    J Urol; 2013 Nov; 190(5):1912-8. PubMed ID: 23669565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of cardiomyogenesis of embryonic stem cells by nitric oxide downstream of AMP-activated protein kinase and mTOR signaling pathways.
    Padmasekar M; Sharifpanah F; Finkensieper A; Wartenberg M; Sauer H
    Stem Cells Dev; 2011 Dec; 20(12):2163-75. PubMed ID: 21470048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.
    Plews RL; Mohd Yusof A; Wang C; Saji M; Zhang X; Chen CS; Ringel MD; Phay JE
    J Clin Endocrinol Metab; 2015 May; 100(5):E748-56. PubMed ID: 25710562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
    Shin DH; Choi YJ; Park JW
    Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses.
    Vasseur S; Afzal S; Tardivel-Lacombe J; Park DS; Iovanna JL; Mak TW
    Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1111-6. PubMed ID: 19144925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression.
    van Vliet T; Varela-Eirin M; Wang B; Borghesan M; Brandenburg SM; Franzin R; Evangelou K; Seelen M; Gorgoulis V; Demaria M
    Mol Cell; 2021 May; 81(9):2041-2052.e6. PubMed ID: 33823141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling.
    Sheng B; Liu J; Li GH
    Comp Biochem Physiol B Biochem Mol Biol; 2012 Sep; 163(1):51-8. PubMed ID: 22564403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.